@article{5c8adbeeca7b4121b1774a4b20bd13fd,
title = "Harmonizing Immune Effector Toxicity Reporting",
abstract = "In this issue of BBMT, a multicenter group of investigators convened by the American Society of Blood and Marrow Transplantation outlines new consensus definitions and grading systems for the most common toxicities associated with immune effector cell therapies, including cytokine release syndrome and the newly named immune cell-associated neurotoxicity syndrome.",
keywords = "Guidelines, Immune effector cells, Toxicity",
author = "Heslop, {Helen E.} and Shpall, {Elizabeth J.}",
note = "Funding Information: Financial disclosure: Conflict of interest statement: H.E.H. is a cofounder with equity in Marker Therapeutics and ViraCyte, has received research support from Cell Medica and Tessa Therapeutics, and has served on advisory boards for Novartis, Gilead Biosciences, and Cytosen. E.J.S. has received research support from Mesoblast and Celgene and has served on advisory boards for Novartis, Magenta, and Adaptimmune. Publisher Copyright: {\textcopyright} 2019 American Society for Blood and Marrow Transplantation",
year = "2019",
month = apr,
doi = "10.1016/j.bbmt.2019.01.001",
language = "English (US)",
volume = "25",
pages = "e121--e122",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",
}